Theragenex

Theragenex is a biotechnology company dedicated to developing innovative gene therapies for the treatment of severe skin diseases and chronic wounds. The company's core technology involves a proprietary non-viral gene delivery platform that enables the localized and sustained expression of therapeutic proteins within the skin. Their lead program focuses on Recessive Dystrophic Epidermolysis Bullosa (RDEB), a devastating genetic condition characterized by fragile, blistering skin. By combining gene therapy with advanced tissue engineering, Theragenex aims to provide curative treatments that significantly improve patient quality of life.